Education
About Us
Working with TipRanks
Follow Us
Esperion (GB:0IIM)
LSE:0IIM
0IIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $3.86
Previous CloseN/A
Volume10.92K
Average Volume (3M)38.67K
Market Cap
$193.29M
Enterprise Value$757.00M
Total Cash (Recent Filing)$20.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 05, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding198,149,410
10 Day Avg. Volume14,677
30 Day Avg. Volume38,666
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda100.01
Forecast
1Y Price Target
$6.31Price Target Upside625.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Esperion News
PremiumCompany Announcements
Esperion Therapeutics Reports Mixed Q1 2025 Results
PremiumCompany Announcements
Esperion Therapeutics Reports Strong Q1 2025 Earnings
---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentThe development of two triple combination products is underway in the U.S., providing potential for significant life-cycle extension and patent protection.
Sales GrowthNexletol/Nexlizet U.S. sales growth should improve driven by strengthened access/reimbursement support, broadened formulary coverage, and new marketing initiatives.
Bears Say
Financial ConcernsEsperion's current cash position is raising concerns about its ability to meet additional priorities and achieve sustained profitability.
Regulatory ChallengesChallenges in regulatory approvals could pose risks to Esperion Therapeutics' future prospects.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.75% Insiders
18.64%
Mutual Funds
27.45% Other Institutional Investors
42.41% Public Companies and
Individual Investors
0IIM FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest share price was $0.85 and its highest was $3.85 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $193.29M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Aug 05, 2025 which is in 88 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 06, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.055.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.15.
How many shares outstanding does Esperion have?
Esperion has 198,149,410 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went down -8.077%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in GB:0IIM
---
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.31 (625.29% Upside)
$6.31 (625.29% Upside)
Blogger Sentiment
Bullish
GB:0IIM Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $29.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
---
0IIM Company Deck
---
0IIM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong overall performance with significant revenue growth, expanded market access, and key pipeline advancements. However, challenges such as seasonal sales impacts and confusion due to policy changes were acknowledged. The highlights, particularly the revenue growth and guideline inclusion, outweigh the lowlights.Read More>---
0IIM Stock 12 Month Forecast
Average Price Target
$6.31
▲(625.29% Upside)
Technical Analysis
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―
---